Vanda Pharmaceuticals (VNDA) said Friday morning that the US Food and Drug Administration has designated the company's VGT-1849A product candidate as an orphan drug to treat polycythemia vera, a rare form of hematologic malignancy affecting about one in every 2,000 people in the country.
The FDA uses orphan drug designation to incentivize the development of prospective treatments for conditions affecting relatively few people. Therapies receiving the designation are eligible for selected tax credits and exemption from certain fees and up to seven years of market exclusivity following regulatory approval.
Vanda shares recently were up 1.5% during Friday morning trade.
Price: 4.70, Change: +0.07, Percent Change: +1.51
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。